公开(公告)号：US20110009597A1

公开(公告)日：2011-01-13

申请号：US12829653

申请日：2010-07-02

申请人： Fei SUN ,  Xitian ZHANG

发明人： Fei SUN ,  Xitian ZHANG

IPC分类号： C07K14/00

CPC分类号： C07K14/37 ,  A61K38/00 ,  C07K14/375 ,  Y02A50/483

摘要： Provided are the use of the recombinant Ganoderma lucidium immunomodulatory protein (rLZ-8) for the manufacturing of a medicament for antitumor, increasing leukocyte and inhibiting immunological rejection and the pharmaceutical composition comprising the rLZ-8 protein, wherein the rLZ-8 protein is expressed from pichia yeast.

摘要翻译： 提供了重组灵芝免疫调节蛋白（rLZ-8）用于制造用于抗肿瘤，增加白细胞和抑制免疫排斥的药物的组合物，以及包含rLZ-8蛋白质的药物组合物，其中rLZ-8蛋白质被表达 来自毕赤酵母。

公开(公告)号：US20150023994A1

公开(公告)日：2015-01-22

申请号：US14511781

申请日：2014-10-10

申请人： Fei SUN ,  Chongyang LIANG ,  Xitian ZHANG

发明人： Fei SUN ,  Chongyang LIANG ,  Xitian ZHANG

IPC分类号： C07K14/37

CPC分类号： C07K14/37 ,  A61K38/00 ,  C07K14/375 ,  Y02A50/483

摘要： Provided are the use of the recombinant Ganoderma lucidum immunomodulatory protein (rLZ-8) for the manufacturing of a medicament for antitumor, increasing leukocyte and inhibiting immunological rejection and the pharmaceutical composition comprising the rLZ-8 protein, wherein the rLZ-8 protein is expressed from pichia yeast.

摘要翻译： 提供了重组灵芝免疫调节蛋白（rLZ-8）用于制造用于抗肿瘤，增加白细胞和抑制免疫排斥的药物的组合物，以及包含rLZ-8蛋白质的药物组合物，其中rLZ-8蛋白质被表达 来自毕赤酵母。

公开(公告)号：US20190282644A1

公开(公告)日：2019-09-19

申请号：US16355349

申请日：2019-03-15

申请人： Fei SUN

发明人： Fei SUN

IPC分类号： A61K36/28 ,  A61K36/57 ,  A61K36/076 ,  A61K36/54 ,  A61K36/884 ,  A61P13/02

摘要： An exemplary formulation including a specific weight ratio of Atractylodes macrocephala to other certain ingredients surprisingly had an antidiuretic effect which is opposite to what was expected from the common general knowledge. One aspect of such a formulation includes Atractylodes macrocephala; at least one other ingredient that can include at least one of Polyporus umbellatus; Poria cocos; Cinnamomum cassia (twig); and at least one of Alisma orientale and Alisma plantago-aquatica. The formulation can be formed with a weight ratio of Atractylodes macrocephala being greater than 25% with respect to the at least one other ingredient. These formulations may be useful in a method for the treatment of excessive urination, the method including administering an effective amount of a formulation as described herein to a patent in need thereof.